MD241115C12500
- 1.45
- -0.85-36.96%
Pediatrix Medical Newsroom
Jefferies Maintains Pediatrix Medical(MD.US) With Buy Rating, Raises Target Price to $18
Jefferies Reaffirms Their Buy Rating on Pediatrix Medical Group (MD)
Cautious Hold Rating for Pediatrix Medical Group Amid Uncertain Long-Term Growth Prospects
Pediatrix Medical Is Maintained at Hold by Deutsche Bank
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $16
Mizuho Securities Maintains Pediatrix Medical(MD.US) With Hold Rating
Pediatrix Medical Group Analyst Ratings
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $13
Jefferies Initiates Pediatrix Medical(MD.US) With Buy Rating, Announces Target Price $14
Buy Rating for Pediatrix Medical Group: Undervalued Stock With Strong Growth and Free Cash Flow Potential
Pediatrix Medical Group Analyst Ratings
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Announces Target Price $10
Truist Adjusts Price Target on Pediatrix Medical Group to $10 From $8, Maintains Hold Rating
Pediatrix Medical Group: Cautious Hold Rating Amidst Financial Growth and Restructuring
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)
UBS Adjusts Pediatrix Medical Group Price Target to $10.50 From $9, Maintains Neutral Rating
Pediatrix Medical Group Analyst Ratings
Pediatrix Medical Group: Strong EBITDA Amidst Strategic Shifts, Yet Uncertainties Prompt Hold Rating
Deutsche Bank Raises Pediatrix Medical Group Price Target to $9 From $8, Maintains Hold Rating
Pediatrix Medical Group (MD) Gets a Hold From Truist Financial